Scott Rocklage may not be super famous like the actors we watch on television but make no mistake he is a celebrity in the healthcare industry. The 5AM Ventures Managing Partner has been heavily involved with the industry on the managing side for more than 30 years. Read more: Scott Racklage | Bloomberg and Scott Racklage | Crunchbase
He has held several leadership positions with different healthcare companies over his storied career. Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, and various R&D positions at Salutar and Catalytica just to name a few.
His skills as a leader has led to FDA approval of three U.S. New Drug Applications for companies he’s involved with. The PhD constantly keeps himself busy. He is Board Chairman of Rennovia, Kinestral, and Cidara.
5AM Ventures was founded in 2002. Rocklage would become a Venture partner a year after its inception and Managing Partner in 2004. The life science-based venture capital firm is still in early stage thus the name 5AM.
A trend that has been sweeping through the healthcare industry as of late is the ability to target specific mutations or genotypes. Individuals like Rocklage are especially excited about this trend as it opens up the door to treat cancer in more unique ways. This trend may be here to stay however since it has contributed to extending and saving lives.
Scott Rocklage possesses a B.S. in Chemistry from the University of California and Berkeley as well as a PhD from MIT. While at the institute of technology he conducted research in the laboratory of Richard R. Schrock, who happens to be a Nobel Peace prize winner.